ResearcherUniversity of VeronaActive in the last 2 years
Francesca Lupo
Matched on OpenAlex author ID A5110193560. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 40
2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 2 papers
Papers 7
- Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
- MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
- Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
- Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
- Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. First author DOI 10.3389/fimmu.2024.1341079↗
- Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
- MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages Co-author DOI 10.1101/759779↗
Closest collaborators
The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vincenzo Corbo · 7 shared papers, 2019–2025 · strength 1.04
- Paper Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. DOI 10.3389/fimmu.2024.1341079↗
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Carmine Carbone · 5 shared papers, 2024–2025 · strength 0.86
- Paper Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. DOI 10.3389/fimmu.2024.1341079↗
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Aldo Scarpa · 6 shared papers, 2019–2025 · strength 0.83
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Antonio Agostini · 4 shared papers, 2024–2025 · strength 0.70
- Paper Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. DOI 10.3389/fimmu.2024.1341079↗
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Sabrina L. D’Agosto · 5 shared papers, 2019–2025 · strength 0.66
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Rita Teresa Lawlor · 5 shared papers, 2019–2025 · strength 0.66
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Elena Fiorini · 5 shared papers, 2019–2025 · strength 0.66
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Francesco De Sanctis · 4 shared papers, 2019–2025 · strength 0.60
- Paper Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. DOI 10.3389/fimmu.2024.1341079↗
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Lisa Veghini · 4 shared papers, 2022–2025 · strength 0.59
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Pietro Delfino · 4 shared papers, 2019–2024 · strength 0.49
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Paper Loss of FGFR4 promotes the malignant phenotype of PDAC. DOI 10.1038/s41388-022-02432-5↗
- Geny Piro · 3 shared papers, 2024–2025 · strength 0.48
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Claudio Luchini · 3 shared papers, 2022–2025 · strength 0.43
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Paper Loss of FGFR4 promotes the malignant phenotype of PDAC. DOI 10.1038/s41388-022-02432-5↗
- Peter J. Bailey · 3 shared papers, 2022–2025 · strength 0.43
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Paper Loss of FGFR4 promotes the malignant phenotype of PDAC. DOI 10.1038/s41388-022-02432-5↗
- Antonia Malinova · 3 shared papers, 2022–2025 · strength 0.43
- Paper MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. DOI 10.1038/s41586-025-08721-9↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Paper Loss of FGFR4 promotes the malignant phenotype of PDAC. DOI 10.1038/s41388-022-02432-5↗
- Vincenzo Bronte · 3 shared papers, 2019–2025 · strength 0.40
- Paper Local ablation disrupts immune evasion in pancreatic cancer. DOI 10.1016/j.canlet.2024.217327↗
- Paper Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. DOI 10.1136/gutjnl-2023-329807↗
- Paper MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macroph… DOI 10.1101/759779↗
- Chiara Musiu · 2 shared papers, 2024–2025 · strength 0.38
- Gabriella Lionetto · 2 shared papers, 2024–2025 · strength 0.38
- Salvatore Paiella · 2 shared papers, 2024–2025 · strength 0.38
- Giuseppe Malleo · 2 shared papers, 2025 · strength 0.34
- Roberto Salvia · 2 shared papers, 2025 · strength 0.34
- David Arthur Tuveson · 2 shared papers, 2024–2025 · strength 0.32
- Claudio Bassi · 2 shared papers, 2022–2025 · strength 0.28
- Michèle Milella · 2 shared papers, 2022–2025 · strength 0.28
- Phyllis F. Cheung · 2 shared papers, 2019–2024 · strength 0.23
- Jens Thomas Siveke · 2 shared papers, 2019–2024 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.